DOP2009000293A - Derivados de piperidina utiles como antagonistas receptores de orexina. - Google Patents

Derivados de piperidina utiles como antagonistas receptores de orexina.

Info

Publication number
DOP2009000293A
DOP2009000293A DO2009000293A DO2009000293A DOP2009000293A DO P2009000293 A DOP2009000293 A DO P2009000293A DO 2009000293 A DO2009000293 A DO 2009000293A DO 2009000293 A DO2009000293 A DO 2009000293A DO P2009000293 A DOP2009000293 A DO P2009000293A
Authority
DO
Dominican Republic
Prior art keywords
orexin
antagonists
receiving
piperidine derivatives
used piperidine
Prior art date
Application number
DO2009000293A
Other languages
English (en)
Inventor
Giuseppe Alvaro
David Amantini
Sandro Belvedere
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0712887A external-priority patent/GB0712887D0/en
Priority claimed from GB0804317A external-priority patent/GB0804317D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DOP2009000293A publication Critical patent/DOP2009000293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Esta invención se refiere a derivados de imidazo[1,2-a]piridin-2-ilmetil piperidina sustituida y a su uso como agentes farmacéuticos.
DO2009000293A 2007-07-03 2009-12-29 Derivados de piperidina utiles como antagonistas receptores de orexina. DOP2009000293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0712887A GB0712887D0 (en) 2007-07-03 2007-07-03 Novel compounds
GB0804317A GB0804317D0 (en) 2008-03-07 2008-03-07 Novel compounds

Publications (1)

Publication Number Publication Date
DOP2009000293A true DOP2009000293A (es) 2010-03-31

Family

ID=39789338

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000293A DOP2009000293A (es) 2007-07-03 2009-12-29 Derivados de piperidina utiles como antagonistas receptores de orexina.

Country Status (18)

Country Link
US (2) US20120095034A1 (es)
EP (1) EP2176258A1 (es)
JP (1) JP2010531848A (es)
KR (1) KR20100030635A (es)
CN (1) CN101796053A (es)
AR (1) AR067396A1 (es)
AU (1) AU2008270294A1 (es)
BR (1) BRPI0812981A2 (es)
CA (1) CA2691638A1 (es)
CL (1) CL2008001951A1 (es)
CO (1) CO6270320A2 (es)
DO (1) DOP2009000293A (es)
EA (1) EA201070091A1 (es)
IL (1) IL202665A0 (es)
MA (1) MA31470B1 (es)
PE (1) PE20090441A1 (es)
TW (1) TW200911242A (es)
WO (1) WO2009003993A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534647A (ja) * 2007-07-27 2010-11-11 アクテリオン ファーマシューティカルズ リミテッド ２−アザ−ビシクロ［３．３．０］オクタン誘導体
WO2009040730A2 (en) * 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
AU2009215243A1 (en) * 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
EP2318367B1 (en) * 2008-04-30 2013-03-20 Actelion Pharmaceuticals Ltd. Piperidine and pyrrolidine compounds
US8129384B2 (en) 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
WO2010060470A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
JP2012509911A (ja) * 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
JP2012509912A (ja) * 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
CN102459229A (zh) 2009-04-24 2012-05-16 葛兰素集团有限公司 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
WO2011138266A1 (en) * 2010-05-03 2011-11-10 Evotec Ag Indolizine and imidazopyridine derivatives as orexin receptor antagonists
JP5847830B2 (ja) * 2010-11-10 2016-01-27 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体拮抗薬として有用なラクタム誘導体
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
GB201101678D0 (en) 2011-02-01 2011-03-16 Rolls Royce Plc A cooling arrangement for a magnetic gearbox
NZ703448A (en) 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
CN104703980B (zh) 2012-10-10 2017-09-22 埃科特莱茵药品有限公司 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
GB201318222D0 (en) * 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
CA2929423C (en) 2013-12-03 2021-12-07 Actelion Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1 ,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
AU2014358766B2 (en) 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US10370380B2 (en) 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
CA3016706A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
AR129309A1 (es) 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1399441B1 (en) * 2001-06-28 2006-07-05 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists

Also Published As

Publication number Publication date
MA31470B1 (fr) 2010-06-01
EP2176258A1 (en) 2010-04-21
CO6270320A2 (es) 2011-04-20
WO2009003993A1 (en) 2009-01-08
PE20090441A1 (es) 2009-05-08
IL202665A0 (en) 2010-06-30
JP2010531848A (ja) 2010-09-30
KR20100030635A (ko) 2010-03-18
US20120095034A1 (en) 2012-04-19
AR067396A1 (es) 2009-10-07
CA2691638A1 (en) 2009-01-08
AU2008270294A1 (en) 2009-01-08
CL2008001951A1 (es) 2009-01-09
EA201070091A1 (ru) 2010-06-30
US20090022670A1 (en) 2009-01-22
CN101796053A (zh) 2010-08-04
TW200911242A (en) 2009-03-16
BRPI0812981A2 (pt) 2014-12-16

Similar Documents

Publication Publication Date Title
DOP2009000293A (es) Derivados de piperidina utiles como antagonistas receptores de orexina.
BRPI0813218A2 (pt) Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
BRPI0809998A2 (pt) Composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina cinase
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
BRPI1012697A2 (pt) derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase
EA201170884A1 (ru) Производные пиперидина, пригодные в качестве антагонистов орексина
BRPI0919738A2 (pt) 3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios
WO2008038251A3 (en) 3-aza-bicyclo[3.1.0]hexane derivatives
BRPI1013933A2 (pt) 3-azabiciclo [4.1.0] heptanos usados como antagonistas de orexina
BRPI0822237A2 (pt) Compostos de imidazo [1,2-a] piridina
SMP201000104B (it) Pirrolo[2,3-D]piridine e loro uso come inibitori di tirosina chinasi
WO2009022311A3 (en) 1,2-diamido-ethylene derivatives as orexin antagonists
DOP2011000175A (es) Compuestos organicos
DK3187225T3 (da) Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
ECSP11011181A (es) Compuestos orgánicos
HN2008001530A (es) Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
UY29439A1 (es) Nuevos compuestos
ATE471938T1 (de) Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
BRPI0815797A2 (pt) Compostos 8-azabiciclo[3.2.1]octil-2-hidroxibanzamida como antagonistas de receptor opióide mu
BRPI0914665A2 (pt) derivados de pirimido[2,1-a]isoquinolin-4-ona substituída
ECSP066486A (es) Antagonistas de receptores de acetilcolina muscarínicos ii
BRPI0814767A2 (pt) Derivados de monoamida como antagonistas do receptor de orexina